Neurotech is scaling fast and the projections are bold, with the global medical BCI market forecast to reach $7.9 billion by 2032 alongside a $34.8 billion brain stimulation market outlook. Yet the clinical reality still moves unevenly, from EEG system costs as low as $0.3 million in academic procurement to regulatory throughput like 46 neurostimulation 510(k) summaries filed in a single 2020 to 2023 window. We put these market forecasts, regulatory signals, safety metrics, and health economics side by side to show where momentum is real and where it is still catching up.
Key Takeaways
- $8.6 billion global neurostimulation market forecast for 2032 (CAGR projected)
- $22.0 billion global neuromodulation market forecast for 2032
- $2.0 billion global EEG systems market forecast for 2032
- 17% of global medical device R&D investment allocated to neuromodulation-related research (surveyed share)
- US FDA cleared 2020–2023: 46 neurostimulation device-related 510(k) summaries (count in FDA database)
- China NMPA issued 2023–2024 priority review policy covering innovative medical devices (regulatory acceleration)
- 280 million people globally live with depression (WHO)
- 50 million people globally live with epilepsy (WHO)
- 2.3 million people in the US have epilepsy (CDC)
- In a clinical review, deep brain stimulation reduced Parkinson’s motor symptoms by ~50% on average (reported effect size)
- Noninvasive TMS trials report effect sizes around Cohen’s d = 0.3–0.6 for depression outcomes in pooled analyses (summary metric)
- Epidural/subdural electrode arrays: BMI decoding accuracies reported between 70% and 90% in 3-class motor imagery tasks (reviewed range)
- Cost per patient for VNS Therapy is commonly reported around $30,000–$40,000 (health-economic review range)
- Cost per QALY threshold in US analyses for DBS commonly falls around $50,000–$100,000/QALY (health-economic framework)
- One health-economic study reports DBS incremental cost-effectiveness ratio (ICER) of ~$60,000 per QALY (reported)
Neurotech is surging with major 2032 market forecasts, expanding funding and faster approvals, despite ongoing clinical and safety tradeoffs.
Related reading
01 · Category
Market Size9 stats
01
$8.6 billion global neurostimulation market forecast for 2032 (CAGR projected)
02
$22.0 billion global neuromodulation market forecast for 2032
03
$2.0 billion global EEG systems market forecast for 2032
04
$7.9 billion global medical BCI market forecast for 2032
05
$3.8 billion global neurotechnology market forecast for 2032
06
$34.8 billion global brain stimulation market forecast for 2032
07
$8.9 billion global neurotechnology market forecast for 2030
08
$6.6 billion global wearable neurotechnology market forecast for 2032
09
$0.3 million median annual cost for a basic EEG system in academic procurement (example pricing)
Interpretation
Market Size Interpretation
The market-size outlook for neurotech through 2032 looks strongly expansionary, with multiple segments forecast in the billions such as $34.8 billion for brain stimulation and $22.0 billion for neuromodulation, signaling sustained growth across both stimulation and BCI adjacent areas.
02 · Category
Industry Trends12 stats
01
17% of global medical device R&D investment allocated to neuromodulation-related research (surveyed share)
02
US FDA cleared 2020–2023: 46 neurostimulation device-related 510(k) summaries (count in FDA database)
03
China NMPA issued 2023–2024 priority review policy covering innovative medical devices (regulatory acceleration)
04
FDA De Novo requests: 2023 neuromodulation/brain device submissions increased vs 2022 (counted in FDA De Novo database)
05
Number of publications on “brain-computer interface” exceeded 20,000 in 2022 (scopus-reported output in review)
06
Market adoption of closed-loop neuromodulation systems in RWE studies: 31% higher symptom improvement vs open-loop in one comparative cohort (clinical results)
07
NSF BRAIN Initiative awards exceeded $500 million cumulative funding by 2021 (program total)
08
FDA total MAUDE neuromodulation adverse event reports: 10,451 records (public MAUDE query window)
09
US NIH issued 2024 RFA for BCI-related research with maximum funding $4.5 million total (program)
10
DTC brain-sensing EEG headband shipments reached 2.5 million units globally in 2021 (industry estimate)
11
BCI/Neurotech startup funding in 2021 exceeded $5.0 billion globally (PitchBook press release figure)
12
Neurotech VC investment in 2023 decreased by 25% YoY to $3.6 billion (industry report headline)
Interpretation
Industry Trends Interpretation
Across industry trends in neurotech, regulatory and clinical momentum is accelerating alongside major investment swings, as neuromodulation received 17% of global medical device R and D and VC funding fell 25% YoY to $3.6 billion in 2023 while FDA clearances and De Novo interest rose, with 46 neurostimulation 510k summaries from 2020 to 2023 and neuromodulation adverse events totaling 10,451 MAUDE reports.
03 · Category
User Adoption6 stats
01
280 million people globally live with depression (WHO)
02
50 million people globally live with epilepsy (WHO)
03
2.3 million people in the US have epilepsy (CDC)
04
1 in 8 people in the US age 55+ have Alzheimer’s (Alzheimer’s Association)
05
In a survey of BCI research participants, 62% reported willingness to use a neurotechnology device for therapeutic goals (study)
06
In a meta-analysis, 73% of trials reported statistically significant symptom improvements with noninvasive brain stimulation (analysis metric)
Interpretation
User Adoption Interpretation
With 62% of BCI research participants saying they are willing to use neurotechnology for therapeutic goals and 73% of noninvasive brain stimulation trials reporting statistically significant symptom improvements, the user adoption outlook looks especially promising even as conditions like 280 million people worldwide live with depression and 50 million live with epilepsy.
More related reading
04 · Category
Performance Metrics11 stats
01
In a clinical review, deep brain stimulation reduced Parkinson’s motor symptoms by ~50% on average (reported effect size)
02
Noninvasive TMS trials report effect sizes around Cohen’s d = 0.3–0.6 for depression outcomes in pooled analyses (summary metric)
03
Epidural/subdural electrode arrays: BMI decoding accuracies reported between 70% and 90% in 3-class motor imagery tasks (reviewed range)
04
ReWalk/Exoskeleton clinical studies report walking speed improvements of ~38% vs baseline in rehabilitation trials (study metric)
05
Transcranial direct current stimulation (tDCS) meta-analysis shows standardized mean difference ~0.35 for negative symptoms in schizophrenia (pooled effect)
06
Neuroimaging-based BCI systems in clinical studies report classification accuracies up to 90% in controlled settings (review)
07
In one randomized trial, cognitive outcomes improved by 0.9 points on MoCA after neurostimulation vs 0.2 points control (trial metric)
08
In a systematic review, stroke recovery improvements measured by Fugl-Meyer Assessment increased by ~6 points with combined neurostimulation vs control (pooled)
09
Seizure reduction with DBS (motor cortex or STN-based targets) reported 40–70% in long-term cohort studies (clinical range)
10
Neurofeedback meta-analysis reports Hedges g = 0.70 average effect for anxiety outcomes (pooled)
11
Noninvasive brain stimulation safety: serious adverse events rate reported 0.4% across pooled studies (systematic review)
Interpretation
Performance Metrics Interpretation
Across performance metrics, neurotech interventions are showing consistently measurable benefits, from about 0.4% serious adverse events and average effect sizes near 0.3 to 0.7 to clinical improvements such as roughly 50% reductions in Parkinson’s motor symptoms and around 38% faster walking speeds.
05 · Category
Cost Analysis11 stats
01
Cost per patient for VNS Therapy is commonly reported around $30,000–$40,000 (health-economic review range)
02
Cost per QALY threshold in US analyses for DBS commonly falls around $50,000–$100,000/QALY (health-economic framework)
03
One health-economic study reports DBS incremental cost-effectiveness ratio (ICER) of ~$60,000per QALY (reported)
04
In a US claims analysis, neurostimulation device utilization increased by 9% per year during 2015–2020 (utilization trend metric)
05
Hospitalization costs for Parkinson’s disease in the US average $11,000per year (economic estimate)
06
In a systematic review, tDCS sessions add ~$200–$500 in direct costs for a typical protocol (cost range)
07
In an economic evaluation, neurofeedback therapy adds ~$1,200total per patient for a standard course (reported)
08
Cochrane review reports mean number of stimulation sessions for depression trials is 10–30 sessions (resource metric)
09
ICER for rTMS in treatment-resistant depression reported at €20,000–€40,000 per QALY in one EU model (range)
10
Average annual cost of care for epilepsy in US claims analysis estimated at $20,000per person per year (economic)
11
Average annual direct medical cost for Alzheimer’s in the US estimated at $11,000per person in 2022 dollars (AA)
Interpretation
Cost Analysis Interpretation
Across cost analysis, neurotech interventions appear to carry meaningful price tags, with per patient figures commonly in the tens of thousands for VNS at about $30,000 to $40,000 and DBS ICERs around $50,000 to $100,000 per QALY, while newer modalities like tDCS add only about $200 to $500 in direct session costs but utilization and care costs for conditions such as Parkinson’s and epilepsy still run into roughly $11,000 to $20,000 annually, reinforcing that long term healthcare spending and cost effectiveness vary widely by therapy and indication.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Neurotech Industry Statistics. Gitnux. https://gitnux.org/neurotech-industry-statistics
MLA
Samuel Norberg. "Neurotech Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neurotech-industry-statistics.
Chicago
Samuel Norberg. 2026. "Neurotech Industry Statistics." Gitnux. https://gitnux.org/neurotech-industry-statistics.
Sources & references
49 datasets cited across this report · attribution is report-level
+28 additional datasets cited (not shown individually)